{"title":"Effect of CCR2-V64I on the Susceptibility of Patients to Cancer","authors":"Xuerou Lu, Lin Li, Xiaoping Zhou","doi":"10.1155/2023/7630422","DOIUrl":null,"url":null,"abstract":"Background. Results from the studies investigating the impact of CC chemokine receptor 2 (CCR2) polymorphism on the risk of cancers are diverse. An updated meta-analysis was conducted to access the relationship between cancer risk and CCR2-V64I polymorphism. Methods. We performed a meta-analysis using STATA 11.0 based on a comprehensive retrieval in WanFang Data, PubMed, China National Knowledge Infrastructure, EMBASE, and Web of Science databases up to January 20, 2023. Results. We included 23 studies in our analysis. Overall, we found CCR2-V64I polymorphism was remarkably related to cancer risk (OR = 1.39, 95% CI = 1.14–1.70, and \n \n P\n =\n 0.001\n \n for A vs G; OR = 1.87, 95% CI = 1.30–2.70, and \n \n P\n =\n 0.001\n \n for AA vs GG; OR = 1.35, 95% CI = 1.03–1.78, and \n \n P\n =\n 0.032\n \n for GA vs GG; OR = 1.45, 95% CI = 1.11–1.90, and \n \n P\n =\n 0.006\n \n for AA + GA vs GG; OR = 1.69, 95% CI = 1.20–2.37, and \n \n P\n =\n 0.003\n \n for AA vs GA + GG). In the ethnicity subgroup analysis, the relevancy between CCR2-V64I polymorphism and an increased cancer risk was discovered among Asians (OR = 1.57, 95% CI = 1.30–1.91, and \n \n P\n <\n 0.001\n \n for A vs G; OR = 2.30, 95% CI = 1.64–3.24, and \n \n P\n <\n 0.001\n \n for AA vs GG; OR = 1.35, 95% CI = 1.10–1.67, and \n \n P\n =\n 0.005\n \n for GA vs GG; OR = 1.52, 95% CI = 1.25–1.87, and \n \n P\n <\n 0.001\n \n for AA + GA vs GG; OR = 2.21, 95% CI = 1.58–3.08, and \n \n P\n <\n 0.001\n \n for AA vs GA + GG). In addition, the subgroup analysis in the light of cancer types demonstrated that CCR2-V64I polymorphism was strongly correlated with bladder cancer (OR = 3.04, 95% CI = 1.09–8.45, and \n \n P\n =\n 0.033\n \n for AA vs GG; OR = 2.84, 95% CI = 1.07–7.09, and \n \n P\n =\n 0.035\n \n for AA vs GA + GG) and oral cancer (OR = 1.83, 95% CI = 1.39-2.42, and \n \n P\n <\n 0.001\n \n for A vs G; OR = 2.04, 95% CI = 1.47–2.85, and \n \n P\n <\n 0.001\n \n for GA vs GG; OR = 2.03, 95% CI = 1.48–2.79, and \n \n P\n <\n 0.001\n \n for AA + GA vs GG). Conclusion. The meta-analysis suggested that CCR2-V64I polymorphism might be a high-risk factor for cancers among Asians, especially for bladder and oral cancers.","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/7630422","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background. Results from the studies investigating the impact of CC chemokine receptor 2 (CCR2) polymorphism on the risk of cancers are diverse. An updated meta-analysis was conducted to access the relationship between cancer risk and CCR2-V64I polymorphism. Methods. We performed a meta-analysis using STATA 11.0 based on a comprehensive retrieval in WanFang Data, PubMed, China National Knowledge Infrastructure, EMBASE, and Web of Science databases up to January 20, 2023. Results. We included 23 studies in our analysis. Overall, we found CCR2-V64I polymorphism was remarkably related to cancer risk (OR = 1.39, 95% CI = 1.14–1.70, and
P
=
0.001
for A vs G; OR = 1.87, 95% CI = 1.30–2.70, and
P
=
0.001
for AA vs GG; OR = 1.35, 95% CI = 1.03–1.78, and
P
=
0.032
for GA vs GG; OR = 1.45, 95% CI = 1.11–1.90, and
P
=
0.006
for AA + GA vs GG; OR = 1.69, 95% CI = 1.20–2.37, and
P
=
0.003
for AA vs GA + GG). In the ethnicity subgroup analysis, the relevancy between CCR2-V64I polymorphism and an increased cancer risk was discovered among Asians (OR = 1.57, 95% CI = 1.30–1.91, and
P
<
0.001
for A vs G; OR = 2.30, 95% CI = 1.64–3.24, and
P
<
0.001
for AA vs GG; OR = 1.35, 95% CI = 1.10–1.67, and
P
=
0.005
for GA vs GG; OR = 1.52, 95% CI = 1.25–1.87, and
P
<
0.001
for AA + GA vs GG; OR = 2.21, 95% CI = 1.58–3.08, and
P
<
0.001
for AA vs GA + GG). In addition, the subgroup analysis in the light of cancer types demonstrated that CCR2-V64I polymorphism was strongly correlated with bladder cancer (OR = 3.04, 95% CI = 1.09–8.45, and
P
=
0.033
for AA vs GG; OR = 2.84, 95% CI = 1.07–7.09, and
P
=
0.035
for AA vs GA + GG) and oral cancer (OR = 1.83, 95% CI = 1.39-2.42, and
P
<
0.001
for A vs G; OR = 2.04, 95% CI = 1.47–2.85, and
P
<
0.001
for GA vs GG; OR = 2.03, 95% CI = 1.48–2.79, and
P
<
0.001
for AA + GA vs GG). Conclusion. The meta-analysis suggested that CCR2-V64I polymorphism might be a high-risk factor for cancers among Asians, especially for bladder and oral cancers.
背景。研究CC趋化因子受体2 (CCR2)多态性对癌症风险影响的研究结果多种多样。我们进行了一项最新的荟萃分析,以获取癌症风险与CCR2-V64I多态性之间的关系。方法。我们基于截至2023年1月20日的万方数据、PubMed、中国国家知识基础设施、EMBASE和Web of Science数据库的综合检索,使用STATA 11.0进行了meta分析。结果。我们在分析中纳入了23项研究。总的来说,我们发现CCR2-V64I多态性与癌症风险显著相关(OR = 1.39, 95% CI = 1.14-1.70, P = 0.001);AA vs GG的OR = 1.87, 95% CI = 1.30-2.70, P = 0.001;GA vs GG的OR = 1.35, 95% CI = 1.03-1.78, P = 0.032;AA + GA vs GG的OR = 1.45, 95% CI = 1.11-1.90, P = 0.006;OR = 1.69, 95% CI = 1.20-2.37, P = 0.003 (AA vs GA + GG)。在种族亚组分析中,亚洲人发现CCR2-V64I多态性与癌症风险增加之间存在相关性(OR = 1.57, 95% CI = 1.30-1.91, A vs G的P < 0.001;AA vs GG的OR = 2.30, 95% CI = 1.64-3.24, P < 0.001;GA vs GG的OR = 1.35, 95% CI = 1.10-1.67, P = 0.005;AA + GA vs GG的OR = 1.52, 95% CI = 1.25-1.87, P < 0.001;OR = 2.21, 95% CI = 1.58-3.08, AA vs GA + GG的P < 0.001)。此外,针对不同癌症类型的亚组分析显示,CCR2-V64I多态性与膀胱癌密切相关(OR = 3.04, 95% CI = 1.09-8.45, P = 0.033);AA vs GA + GG的OR = 2.84, 95% CI = 1.07-7.09, P = 0.035)和口腔癌(OR = 1.83, 95% CI = 1.39-2.42, A vs G的P < 0.001;GA vs GG的OR = 2.04, 95% CI = 1.47-2.85, P < 0.001;OR = 2.03, 95% CI = 1.48-2.79, AA + GA vs GG的P < 0.001)。结论。荟萃分析表明,CCR2-V64I多态性可能是亚洲人患癌症的高危因素,尤其是膀胱癌和口腔癌。
期刊介绍:
The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of:
- Primary, secondary and tertiary care for cancer patients
- Multidisciplinary and service-user involvement in cancer care
- Rehabilitation, supportive, palliative and end of life care for cancer patients
- Policy, service development and healthcare evaluation in cancer care
- Psychosocial interventions for patients and family members
- International perspectives on cancer care